Christian Blank
Led NADINA, which showed giving immunotherapy before melanoma surgery beats giving it after.
Christian Blank pioneered neoadjuvant checkpoint blockade in melanoma through OpACIN, PRADO, and the phase 3 NADINA trial, which established response-directed neoadjuvant nivolumab plus ipilimumab.
| Title | Journal | Year |
|---|---|---|
| Neoadjuvant nivolumab and ipilimumab in resectable stage III melanoma (NADINA) | NEJM | 2024 |
Pages like this
not linked directly; found by shared links- TermMajor pathological response (MPR)
Shares NADINA, Treat the draining lymph node before removing it, Use pre-surgery immunotherapy windows as the field's biomarker engine, Neoadjuvant / adjuvant / perioperative.
- PersonJohn Haanen
Shares Treat the draining lymph node before removing it, NADINA: two doses of ipilimumab plus nivolumab before surgery beat a year of nivolumab after surgery in stage III melanoma, Netherlands Cancer Institute (NKI-AvL), Ipilimumab.
- TrialNICHE-2
Shares Use pre-surgery immunotherapy windows as the field's biomarker engine, Netherlands Cancer Institute (NKI-AvL), Neoadjuvant / adjuvant / perioperative, Ipilimumab.
- PersonMyriam Chalabi
Shares Use pre-surgery immunotherapy windows as the field's biomarker engine, Netherlands Cancer Institute (NKI-AvL), Ipilimumab, Nivolumab.
- TrialCheckMate 816
Shares Use pre-surgery immunotherapy windows as the field's biomarker engine, Neoadjuvant / adjuvant / perioperative, Nivolumab.
- PairingNeoadjuvant immunotherapy → response-adapted adjuvant
Shares NADINA, Ipilimumab, Nivolumab, Melanoma.
- PairingImmunotherapy first, then BRAF/MEK (BRAF-mutant melanoma)
Shares Ipilimumab, Nivolumab, Melanoma.
- InstitutionDartmouth Cancer Center
Shares Ipilimumab, Nivolumab, Melanoma.